See more : Geomega Resources Inc. (GOMRF) Income Statement Analysis – Financial Results
Complete financial analysis of Getein Biotech, Inc (603387.SS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Getein Biotech, Inc, a leading company in the Medical – Devices industry within the Healthcare sector.
- Kohl’s Corporation (KSS) Income Statement Analysis – Financial Results
- Marten Transport, Ltd. (MRTN) Income Statement Analysis – Financial Results
- Evergold Corp. (EVER.V) Income Statement Analysis – Financial Results
- Supernus Pharmaceuticals, Inc. (SUPN) Income Statement Analysis – Financial Results
- Origin Materials, Inc. (ORGNW) Income Statement Analysis – Financial Results
Getein Biotech, Inc (603387.SS)
About Getein Biotech, Inc
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic products in China and internationally. The company provides diagnostic reagents and analyzers; calibrators; reagent raw materials, such as monoclonal and polyclonal antibodies, antigen, antiserum, and microsphere; and cardiac marker, inflammation, renal function, coagulation, thyroid function, fertility, diabetes care, and thrombus products. It also offers products in the area of cardiovascular, inflammatory, diabetes, fertility, renal, liver, and others. The company was founded in 2002 and is headquartered in Nanjing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.37B | 1.82B | 1.40B | 1.12B | 968.20M | 686.24M | 488.58M | 369.09M | 276.42M | 210.29M | 154.20M | 73.64M |
| Cost of Revenue | 446.07M | 636.39M | 482.46M | 415.30M | 263.41M | 144.77M | 87.33M | 69.35M | 47.51M | 34.01M | 25.59M | 10.29M |
| Gross Profit | 923.10M | 1.19B | 919.24M | 708.04M | 704.79M | 541.47M | 401.25M | 299.74M | 228.91M | 176.28M | 128.61M | 63.35M |
| Gross Profit Ratio | 67.42% | 65.07% | 65.58% | 63.03% | 72.79% | 78.90% | 82.13% | 81.21% | 82.81% | 83.83% | 83.41% | 86.02% |
| Research & Development | 217.99M | 223.22M | 163.39M | 119.07M | 104.73M | 80.60M | 54.04M | 39.28M | 31.92M | 30.00M | 14.00M | 7.95M |
| General & Administrative | 27.56M | 34.85M | 29.97M | 25.95M | 25.01M | 20.39M | 13.74M | 9.76M | 14.11M | 17.61M | 27.86M | 15.52M |
| Selling & Marketing | 347.44M | 303.32M | 233.51M | 182.74M | 174.10M | 152.05M | 101.85M | 74.78M | 51.69M | 35.00M | 28.94M | 24.62M |
| SG&A | 375.00M | 338.18M | 263.48M | 208.69M | 199.12M | 172.45M | 115.58M | 84.54M | 65.80M | 52.60M | 56.81M | 40.14M |
| Other Expenses | -16.34M | 69.02M | 56.04M | 33.00M | 22.79M | 4.48M | 858.18K | 9.12M | 11.13M | 8.11M | 6.28M | 3.42M |
| Operating Expenses | 616.51M | 630.42M | 482.91M | 360.76M | 326.63M | 289.36M | 186.01M | 150.49M | 118.82M | 95.93M | 59.26M | 41.26M |
| Cost & Expenses | 1.06B | 1.27B | 965.37M | 776.05M | 590.05M | 434.12M | 273.34M | 219.84M | 166.33M | 129.94M | 84.85M | 51.56M |
| Interest Income | 56.54M | 29.44M | 20.12M | 17.35M | 2.72M | 2.65M | 2.00M | 89.62K | 38.23K | 60.07K | 0.00 | 43.27K |
| Interest Expense | 17.48M | 16.61M | 14.31M | 6.22M | 1.44M | 3.77M | 1.49M | 364.54K | 43.72K | 25.17K | 0.00 | 12.66K |
| Depreciation & Amortization | 101.85M | 78.14M | 56.53M | 41.95M | 33.64M | 27.76M | 22.43M | 6.60M | 10.18M | 6.75M | 857.77K | 826.18K |
| EBITDA | 426.89M | 654.55M | 522.11M | 424.74M | 431.44M | 276.87M | 246.38M | 164.87M | 120.28M | 87.10M | 70.27M | 22.96M |
| EBITDA Ratio | 31.18% | 38.45% | 37.50% | 35.98% | 44.47% | 40.84% | 48.74% | 44.83% | 43.90% | 41.17% | 45.57% | 30.57% |
| Operating Income | 306.59M | 563.26M | 452.79M | 378.00M | 398.91M | 282.79M | 223.10M | 152.62M | 111.81M | 80.90M | 69.41M | 21.69M |
| Operating Income Ratio | 22.39% | 30.92% | 32.30% | 33.65% | 41.20% | 41.21% | 45.66% | 41.35% | 40.45% | 38.47% | 45.02% | 29.45% |
| Total Other Income/Expenses | -1.65M | -4.00M | -1.16M | 66.55M | -2.77M | 46.56M | 624.31K | 12.96M | 11.13M | 8.07M | 7.25M | 3.45M |
| Income Before Tax | 304.94M | 559.98M | 451.63M | 374.04M | 395.97M | 287.27M | 223.95M | 161.67M | 122.94M | 88.97M | 75.68M | 25.10M |
| Income Before Tax Ratio | 22.27% | 30.74% | 32.22% | 33.30% | 40.90% | 41.86% | 45.84% | 43.80% | 44.48% | 42.31% | 49.08% | 34.09% |
| Income Tax Expense | 20.86M | 56.03M | 39.62M | 43.73M | 46.02M | 36.63M | 30.17M | 23.35M | 18.15M | 14.41M | 10.05M | 3.15M |
| Net Income | 279.77M | 498.91M | 398.99M | 304.73M | 339.67M | 249.61M | 193.99M | 138.36M | 105.07M | 75.14M | 65.63M | 21.96M |
| Net Income Ratio | 20.43% | 27.38% | 28.46% | 27.13% | 35.08% | 36.37% | 39.70% | 37.49% | 38.01% | 35.73% | 42.56% | 29.82% |
| EPS | 0.55 | 0.98 | 0.79 | 0.60 | 0.67 | 0.49 | 0.45 | 0.36 | 0.28 | 0.20 | 0.24 | 0.08 |
| EPS Diluted | 0.55 | 0.98 | 0.79 | 0.60 | 0.66 | 0.49 | 0.45 | 0.36 | 0.28 | 0.20 | 0.24 | 0.08 |
| Weighted Avg Shares Out | 508.68M | 507.15M | 507.81M | 509.02M | 507.75M | 507.09M | 432.72M | 379.65M | 380.78M | 379.79M | 271.28M | 271.28M |
| Weighted Avg Shares Out (Dil) | 508.68M | 507.15M | 507.81M | 509.02M | 512.12M | 509.62M | 432.77M | 379.65M | 380.78M | 379.79M | 271.28M | 271.28M |
Source: https://incomestatements.info
Category: Stock Reports